Kanıta Dayalı Tıp Açısından Over Rezervini Etkileyen Bir Tedavi Var Mı?

Zhu Q, Li Y, Ma J, et al. Potential factors result in dimi- nished ovarian reserve: a comprehensive review. Journal of ovarian research. 2023;16(1):208. doi: 10.1186/ s13048-023-01296-x.

Jirge PR. Ovarian reserve tests. Journal of human repro- ductive sciences. 2011;4(3):108-113. doi: 10.4103/0974- 1208.92283.

Jiao Z, Bukulmez O. Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve. Journal of assisted reproduc- tion and genetics. 2021;38(10):2507-2517. doi: 10.1007/ s10815-021-02246-6.

Zhu Z, Xu W, Liu L. Ovarian aging: mechanisms and intervention strategies. Medical Review. 2022;2(6):590- 610. doi: 10.1515/mr-2022-0031.

Conforti A, Carbone L, Di Girolamo R, et al. Thera- peutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility. 2025;123(3):457-476. doi: 10.1016/j.fertns- tert.2024.09.038.

Bishop LA, Richter KS, Patounakis G, et al. Dimi- nished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral fol- licle count is not associated with pregnancy loss in younger in vitro fertilization patients. Fertility and Sterility. 2017;108(6):980-987. doi: 10.1016/j.fertns- tert.2017.09.011.

Zhao M, Huan Q, Huang L, et al. Pregnancy outcomes of intrauterine insemination in young patients with di- minished ovarian reserve: a multicenter cohort study. European journal of medical research. 2023;28(1):402. doi: 10.1186/s40001-023-01377-z.

Neves AR, Montoya-Botero P, Polyzos NP. The Role of Androgen Supplementation in Women With Diminished Ovarian Reserve: Time to Randomize, Not Me- ta-Analyze. Frontiers of Endocrinology. 2021;12:653857. doi: 10.3389/fendo.2021.653857.

Orvieto R. Pretreatment: Does it improve quantity or quality? Fertility and Sterility. 2022;117(4):657-663. doi: 10.1016/j.fertnstert.2022.01.029.

Sönmezer M, Ozmen B, Cil AP, et al. Dehydroepiand- rosterone supplementation improves ovarian response and cycle outcome in poor responders. Reproductive biomedicine online. 2009;19(4):508-513. doi: 10.1016/j. rbmo.2009.06.006.

Chern CU, Tsui KH, Vitale SG, et al. Dehydroepiand- rosterone (DHEA) supplementation improves in vit- ro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study. Reproductive bi- ology and endocrinology. 2018;16(1):90. doi: 10.1186/ s12958-018-0409-z.

Li J, Yuan H, Chen Y, et al. A meta-analysis of dehyd- roepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vit- ro fertilization or intracytoplasmic sperm injection. International journal of gynaecology and obstetrics. 2015;131(3):240-245. doi: 10.1016/j.ijgo.2015.06.028.

Qin JC, Fan L, Qin AP. The effect of dehydroepiand- rosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evi- dence from a meta-analysis. Journal of Gynecololgy Obstetrics and Human Reproduction. 2017;46(1):1-7. doi: 10.1016/j.jgyn.2016.01.002.

Orvieto R, Homburg R, Farhi J, et al. A new concept of cotreatment with human growth hormone and menotropins in ovulation induction protocols. Medical Hypotheses. 1997;49(5):413-415. doi: 10.1016/s0306- 9877(97)90088-8.

Adashi EY, Resnick CE, D’Ercole AJ, et al. Insulin-li- ke growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Reviews. 1985;6(3):400-420. doi: 10.1210/edrv-6-3-400.

Hart RJ. Use of Growth Hormone in the IVF Treat- ment of Women With Poor Ovarian Reserve. Frontiers of Endocrinology. 2019;10:500. doi: 10.3389/fen- do.2019.00500.

Tamura H, Takasaki A, Taketani T, et al. Melatonin as a free radical scavenger in the ovarian follicle. Endocrine Journal. 2013;60(1):1-13. doi: 10.1507/endocrj.ej12- 0263.

Tamura H, Jozaki M, Tanabe M, et al. Importance of Melatonin in Assisted Reproductive Technology and Ovarian Aging. International Journal of Molecular Sciences. 2020;21(3):1135. doi: 10.3390/ijms21031135.

Jahromi BN, Sadeghi S, Alipour S, et al. Effect of Me- latonin on the Outcome of Assisted Reproductive Technique Cycles in Women with Diminished Ovarian Reserve: A Double-Blinded Randomized Clinical Trial. Iranian Journal of Medical Sciences. 2017;42(1):73-78.

Ma L, Cai L, Hu M, et al. Coenzyme Q10 supp- lementation of human oocyte in vitro maturati- on reduces postmeiotic aneuploidies. Fertility and Sterility. 2020;114(2):331-337. doi: 10.1016/j.fertns- tert.2020.04.002.

Bentov Y, Hannam T, Jurisicova A, et al. Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment. Clinical Medi- cine Insights Reproductive Health. 2014;8:31-36. doi: 10.4137/CMRH.S14681.

Xia T, Ma R-h, Mu W, et al. Traditional Chinese me- dicine for diminished ovarian reserve: a systematic review and meta-analysis. Chinese Herbal Medicines. 2014;6(2):93-102. doi: 10.1016/s1674-6384(14)60014- 9.

Yin J, Chang H-M, Li R, et al. Recent progress in the treatment of women with diminished ovarian reserve. Gynecology and Obstetrics Clinical Medicine. 2021;1(4):186-189. doi: 10.1016/j.gocm.2021.10.004.

Lee HJ, Selesniemi K, Niikura Y, et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. Journal of Clinical Oncology. 2007;25(22):3198-3204. doi: 10.1200/JCO.2006.10.3028.

Huang Q, Liu B, Jiang R, et al. G-CSF-mobilized pe- ripheral blood mononuclear cells combined with plateletrich plasma accelerate restoration of ovarian func- tion in cyclophosphamide-induced POI rats. Biology of Reproduction. 2019;101(1):91-101. doi: 10.1093/biolre/ ioz077.

Vural B, Duruksu G, Vural F, et al. Effects of VEGF + Mesenchymal Stem Cells and Platelet-Rich Plasma on Inbred Rat Ovarian Functions in Cyclophosphami- de-Induced Premature Ovarian Insufficiency Model. Stem Cell Reviews and Reports. 2019;15(4):558-573. doi: 10.1007/s12015-019-09892-5.

Song D, Zhong Y, Qian C, et al. Human Umbilical Cord Mesenchymal Stem Cells Therapy in Cyclophosphami de Induced Premature Ovarian Failure Rat Model. Bi- oMed Research International. 2016;2016:2517514. doi: 10.1155/2016/2517514.

Mohamed SA, Shalaby S, Brakta S, et al. Umbilical Cord Blood Mesenchymal Stem Cells as an Inferti- lity Treatment for Chemotherapy Induced Premature Ovarian Insufficiency. Biomedicines. 2019;7(1):7. doi: 10.3390/biomedicines7010007.

Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Research & Theraphy. 2019;10(1):46. doi: 10.1186/s13287-019-1136-x.

Elfayomy AK, Almasry SM, El-Tarhouny SA, et al. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epit- helium in a rat model of premature ovarian failure: Possible direct and indirect effects. Tissue and Cell. 2016;48(4):370-382. doi: 10.1016/j.tice.2016.05.001.

Ding C, Zhu L, Shen H, et al. Exosomal miRNA-17- 5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. Stem Cells. 2020;38(9):1137-1148. doi: 10.1002/stem.3204.

Edessy M, Hosni HN, Shady Y, et al. Autologous stem cells therapy, the first baby of idiopathic premature ova- rian failure. Acta Medica International. 2016;3(1):19- 23. doi: 10.5530/ami.2016.1.7.

Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertility and Sterility. 2018;110(3):496-505.e1. doi: 10.1016/j. fertnstert.2018.04.025.

Prokurat M, Grudnik K, Niemczyk W, et al. Platelet-Ri- ch Plasma - a remedy present in every human being. History, functioning, and the benefits of therapy using it. Polski merkuriusz lekarski: organ Polskiego Towar- zystwa Lekarskiego. 2024;52(2):240-245. doi: 10.36740/ Merkur202402114.

Gruber R. How to explain the beneficial effects of pla- telet-rich plasma. Periodontol 2000. 2025;97(1):95-103. doi: 10.1111/prd.12565.

Sfakianoudis K, Simopoulou M, Nitsos N, et al. Au- tologous Platelet-Rich Plasma Treatment Enables Pregnancy for a Woman in Premature Menopause. Journal of Clinical Medicine. 2018;8(1):1. doi: 10.3390/ jcm8010001.

Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. Journal of Clinical Medicine. 2020;9(6):1809. doi: 10.3390/ jcm9061809.

Faddy MJ, Gosden RG. A model conforming the decli- ne in follicle numbers to the age of menopause in wo- men. Human Reproduction. 1996;11(7):1484-1486. doi: 10.1093/oxfordjournals.humrep.a019422.

Ford EA, Beckett EL, Roman SD, et al. Advances in hu- man primordial follicle activation and premature ovari- an insufficiency. Reproduction: the official journal of the Society fort he Study of Fertility. 2020;159(1):R15-R29. doi: 10.1530/REP-19-0201.

Rosario R, Anderson RA. Novel approaches to fer- tility restoration in women with premature ovarian insufficiency. Climacteric: the journal of the Interna- tionalMenopause Society. 2021;24(5):491-497. doi:

10.1080/13697137.2020.1856806.

Guo Y, Kwiatkowski DJ. Equivalent benefit of rapam- ycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Molecular Cancer Research. 2013;11(5):467- 743. doi: 10.1158/1541-7786.MCR-12-0605.

Kawamura K, Cheng Y, Suzuki N, et al. Hippo sig- naling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(43):17474-17479. doi: 10.1073/ pnas.1312830110.

Suzuki N, Yoshioka N, Takae S, et al. Successful ferti- lity preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Human Reproduction. 2015;30(3):608-615. doi: 10.1093/humrep/deu353.

Grosbois J, Demeestere I. Dynamics of PI3K and Hip- po signaling pathways during in vitro human follicle activation. Human Reproduction. 2018;33(9):1705- 1714. doi: 10.1093/humrep/dey250.

Zhu Q, Li Y, Ma J, et al. Potential factors result in dimi- nished ovarian reserve: a comprehensive review. Journal of ovarian research. 2023;16(1):208. doi: 10.1186/ s13048-023-01296-x.

Jirge PR. Ovarian reserve tests. Journal of human repro- ductive sciences. 2011;4(3):108-113. doi: 10.4103/0974- 1208.92283.

Jiao Z, Bukulmez O. Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve. Journal of assisted reproduc- tion and genetics. 2021;38(10):2507-2517. doi: 10.1007/ s10815-021-02246-6.

Zhu Z, Xu W, Liu L. Ovarian aging: mechanisms and intervention strategies. Medical Review. 2022;2(6):590- 610. doi: 10.1515/mr-2022-0031.

Conforti A, Carbone L, Di Girolamo R, et al. Thera- peutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility. 2025;123(3):457-476. doi: 10.1016/j.fertns- tert.2024.09.038.

Bishop LA, Richter KS, Patounakis G, et al. Dimi- nished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral fol- licle count is not associated with pregnancy loss in younger in vitro fertilization patients. Fertility and Sterility. 2017;108(6):980-987. doi: 10.1016/j.fertns- tert.2017.09.011.

Zhao M, Huan Q, Huang L, et al. Pregnancy outcomes of intrauterine insemination in young patients with di- minished ovarian reserve: a multicenter cohort study. European journal of medical research. 2023;28(1):402. doi: 10.1186/s40001-023-01377-z.

Neves AR, Montoya-Botero P, Polyzos NP. The Role of Androgen Supplementation in Women With Diminished Ovarian Reserve: Time to Randomize, Not Me- ta-Analyze. Frontiers of Endocrinology. 2021;12:653857. doi: 10.3389/fendo.2021.653857.

Orvieto R. Pretreatment: Does it improve quantity or quality? Fertility and Sterility. 2022;117(4):657-663. doi: 10.1016/j.fertnstert.2022.01.029.

Sönmezer M, Ozmen B, Cil AP, et al. Dehydroepiand- rosterone supplementation improves ovarian response and cycle outcome in poor responders. Reproductive biomedicine online. 2009;19(4):508-513. doi: 10.1016/j. rbmo.2009.06.006.

Chern CU, Tsui KH, Vitale SG, et al. Dehydroepiand- rosterone (DHEA) supplementation improves in vit- ro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study. Reproductive bi- ology and endocrinology. 2018;16(1):90. doi: 10.1186/ s12958-018-0409-z.

Li J, Yuan H, Chen Y, et al. A meta-analysis of dehyd- roepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vit- ro fertilization or intracytoplasmic sperm injection. International journal of gynaecology and obstetrics. 2015;131(3):240-245. doi: 10.1016/j.ijgo.2015.06.028.

Qin JC, Fan L, Qin AP. The effect of dehydroepiand- rosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evi- dence from a meta-analysis. Journal of Gynecololgy Obstetrics and Human Reproduction. 2017;46(1):1-7. doi: 10.1016/j.jgyn.2016.01.002.

Orvieto R, Homburg R, Farhi J, et al. A new concept of cotreatment with human growth hormone and menotropins in ovulation induction protocols. Medical Hypotheses. 1997;49(5):413-415. doi: 10.1016/s0306- 9877(97)90088-8.

Adashi EY, Resnick CE, D’Ercole AJ, et al. Insulin-li- ke growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Reviews. 1985;6(3):400-420. doi: 10.1210/edrv-6-3-400.

Hart RJ. Use of Growth Hormone in the IVF Treat- ment of Women With Poor Ovarian Reserve. Frontiers of Endocrinology. 2019;10:500. doi: 10.3389/fen- do.2019.00500.

Tamura H, Takasaki A, Taketani T, et al. Melatonin as a free radical scavenger in the ovarian follicle. Endocrine Journal. 2013;60(1):1-13. doi: 10.1507/endocrj.ej12- 0263.

Tamura H, Jozaki M, Tanabe M, et al. Importance of Melatonin in Assisted Reproductive Technology and Ovarian Aging. International Journal of Molecular Sciences. 2020;21(3):1135. doi: 10.3390/ijms21031135.

Jahromi BN, Sadeghi S, Alipour S, et al. Effect of Me- latonin on the Outcome of Assisted Reproductive Technique Cycles in Women with Diminished Ovarian Reserve: A Double-Blinded Randomized Clinical Trial. Iranian Journal of Medical Sciences. 2017;42(1):73-78.

Ma L, Cai L, Hu M, et al. Coenzyme Q10 supp- lementation of human oocyte in vitro maturati- on reduces postmeiotic aneuploidies. Fertility and Sterility. 2020;114(2):331-337. doi: 10.1016/j.fertns- tert.2020.04.002.

Bentov Y, Hannam T, Jurisicova A, et al. Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment. Clinical Medi- cine Insights Reproductive Health. 2014;8:31-36. doi: 10.4137/CMRH.S14681.

Xia T, Ma R-h, Mu W, et al. Traditional Chinese me- dicine for diminished ovarian reserve: a systematic review and meta-analysis. Chinese Herbal Medicines. 2014;6(2):93-102. doi: 10.1016/s1674-6384(14)60014- 9.

Yin J, Chang H-M, Li R, et al. Recent progress in the treatment of women with diminished ovarian reserve. Gynecology and Obstetrics Clinical Medicine. 2021;1(4):186-189. doi: 10.1016/j.gocm.2021.10.004.

Lee HJ, Selesniemi K, Niikura Y, et al. Bone marrow transplantation generates immature oocytes and rescues long-term fertility in a preclinical mouse model of chemotherapy-induced premature ovarian failure. Journal of Clinical Oncology. 2007;25(22):3198-3204. doi: 10.1200/JCO.2006.10.3028.

Huang Q, Liu B, Jiang R, et al. G-CSF-mobilized pe- ripheral blood mononuclear cells combined with plateletrich plasma accelerate restoration of ovarian func- tion in cyclophosphamide-induced POI rats. Biology of Reproduction. 2019;101(1):91-101. doi: 10.1093/biolre/ ioz077.

Vural B, Duruksu G, Vural F, et al. Effects of VEGF + Mesenchymal Stem Cells and Platelet-Rich Plasma on Inbred Rat Ovarian Functions in Cyclophosphami- de-Induced Premature Ovarian Insufficiency Model. Stem Cell Reviews and Reports. 2019;15(4):558-573. doi: 10.1007/s12015-019-09892-5.

Song D, Zhong Y, Qian C, et al. Human Umbilical Cord Mesenchymal Stem Cells Therapy in Cyclophosphami de Induced Premature Ovarian Failure Rat Model. Bi- oMed Research International. 2016;2016:2517514. doi: 10.1155/2016/2517514.

Mohamed SA, Shalaby S, Brakta S, et al. Umbilical Cord Blood Mesenchymal Stem Cells as an Inferti- lity Treatment for Chemotherapy Induced Premature Ovarian Insufficiency. Biomedicines. 2019;7(1):7. doi: 10.3390/biomedicines7010007.

Ling L, Feng X, Wei T, et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Research & Theraphy. 2019;10(1):46. doi: 10.1186/s13287-019-1136-x.

Elfayomy AK, Almasry SM, El-Tarhouny SA, et al. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epit- helium in a rat model of premature ovarian failure: Possible direct and indirect effects. Tissue and Cell. 2016;48(4):370-382. doi: 10.1016/j.tice.2016.05.001.

Ding C, Zhu L, Shen H, et al. Exosomal miRNA-17- 5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. Stem Cells. 2020;38(9):1137-1148. doi: 10.1002/stem.3204.

Edessy M, Hosni HN, Shady Y, et al. Autologous stem cells therapy, the first baby of idiopathic premature ova- rian failure. Acta Medica International. 2016;3(1):19- 23. doi: 10.5530/ami.2016.1.7.

Herraiz S, Romeu M, Buigues A, et al. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertility and Sterility. 2018;110(3):496-505.e1. doi: 10.1016/j. fertnstert.2018.04.025.

Prokurat M, Grudnik K, Niemczyk W, et al. Platelet-Ri- ch Plasma - a remedy present in every human being. History, functioning, and the benefits of therapy using it. Polski merkuriusz lekarski: organ Polskiego Towar- zystwa Lekarskiego. 2024;52(2):240-245. doi: 10.36740/ Merkur202402114.

Gruber R. How to explain the beneficial effects of pla- telet-rich plasma. Periodontol 2000. 2025;97(1):95-103. doi: 10.1111/prd.12565.

Sfakianoudis K, Simopoulou M, Nitsos N, et al. Au- tologous Platelet-Rich Plasma Treatment Enables Pregnancy for a Woman in Premature Menopause. Journal of Clinical Medicine. 2018;8(1):1. doi: 10.3390/ jcm8010001.

Sfakianoudis K, Simopoulou M, Grigoriadis S, et al. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. Journal of Clinical Medicine. 2020;9(6):1809. doi: 10.3390/ jcm9061809.

Faddy MJ, Gosden RG. A model conforming the decli- ne in follicle numbers to the age of menopause in wo- men. Human Reproduction. 1996;11(7):1484-1486. doi: 10.1093/oxfordjournals.humrep.a019422.

Ford EA, Beckett EL, Roman SD, et al. Advances in hu- man primordial follicle activation and premature ovari- an insufficiency. Reproduction: the official journal of the Society fort he Study of Fertility. 2020;159(1):R15-R29. doi: 10.1530/REP-19-0201.

Rosario R, Anderson RA. Novel approaches to fer- tility restoration in women with premature ovarian insufficiency. Climacteric: the journal of the Interna- tionalMenopause Society. 2021;24(5):491-497. doi:

10.1080/13697137.2020.1856806.

Guo Y, Kwiatkowski DJ. Equivalent benefit of rapam- ycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Molecular Cancer Research. 2013;11(5):467- 743. doi: 10.1158/1541-7786.MCR-12-0605.

Kawamura K, Cheng Y, Suzuki N, et al. Hippo sig- naling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(43):17474-17479. doi: 10.1073/ pnas.1312830110.

Suzuki N, Yoshioka N, Takae S, et al. Successful ferti- lity preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Human Reproduction. 2015;30(3):608-615. doi: 10.1093/humrep/deu353.

Grosbois J, Demeestere I. Dynamics of PI3K and Hip- po signaling pathways during in vitro human follicle activation. Human Reproduction. 2018;33(9):1705- 1714. doi: 10.1093/humrep/dey250.